Literature DB >> 29689237

Dutch Lung Surgery Audit: A National Audit Comprising Lung and Thoracic Surgery Patients.

Martijn Ten Berge1, Naomi Beck2, David Jonathan Heineman3, Ronald Damhuis4, Willem Hans Steup5, Pieter Jan van Huijstee5, Jan Peter Eerenberg6, Eelco Veen7, Alexander Maat8, Michel Versteegh9, Thomas van Brakel9, Wilhemina Hendrika Schreurs3, Michel Wilhelmus Wouters10.   

Abstract

BACKGROUND: The nationwide Dutch Lung Surgery Audit (DLSA) started in 2012 to monitor and evaluate the quality of lung operations in The Netherlands as an improvement tool. This outline describes the establishment, structure, and organization of the audit by the Dutch Society of Lung Surgeons (NVvL) and the Dutch Society of Cardiothoracic Surgeons (NVT), in collaboration with the Dutch Institute for Clinical Auditing. In addition, the first 4-year results are presented.
METHODS: The NVvL and NVT initiated a web-based registration, including weekly updated online feedback for participating hospitals. Data verification by external data managers is performed on regular basis. The audit is incorporated in national quality improvement programs, and participation in the DLSA is mandatory by health insurance organizations and the National Healthcare Inspectorate.
RESULTS: Between January 1, 2012, and December 31, 2015, all hospitals performing lung operations participated, and a total of 19,557 patients were registered from which almost half comprised lung cancer patients. Nationwide the guideline adherence increased over the years, and 96.5% of lung cancer patients were discussed in preoperative multidisciplinary teams. Overall postoperative complications and mortality after non-small cell lung cancer operations were 15.5% and 2.0%, respectively.
CONCLUSIONS: The audit provides reliable benchmarked information for caregivers and hospital management with potential to start local, regional, or national improvement initiatives. Currently, the audit is further completed with data from nonsurgical lung cancer patients, including treatment data from pulmonary oncologists and radiation oncologists. This will ultimately provide a comprehensive overview of lung cancer treatment in The Netherlands.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29689237     DOI: 10.1016/j.athoracsur.2018.03.049

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Lessons learned from the Dutch Institute for Clinical Auditing: the Dutch model for quality assurance in lung cancer treatment.

Authors:  Naomi Beck; Fieke Hoeijmakers; Erwin M Wiegman; Hans J M Smit; Franz M Schramel; Willem H Steup; Ad F T M Verhagen; Wilhelmina H Schreurs; Michel W J M Wouters
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  'Care for Outcomes': systematic development of a set of outcome indicators to improve patient-relevant outcomes for patients with lung cancer.

Authors:  Christine M Cramer-van der Welle; Lotte van Loenhout; Ben Eem van den Borne; Franz Mnh Schramel; Lea M Dijksman
Journal:  BMJ Open       Date:  2021-01-15       Impact factor: 2.692

3.  National Thoracic Surgery Standards Implementation: Barriers, Enablers, and Opportunities.

Authors:  Angel Arnaout; Anubha Prashad; Nadine Dunk; Jess Rogers; Annemarie Edwards; Mary Argent-Katwala; Christian Finley
Journal:  Curr Oncol       Date:  2021-01-13       Impact factor: 3.677

4.  Textbook outcome as a composite outcome measure in non-small-cell lung cancer surgery.

Authors:  Martijn G Ten Berge; Naomi Beck; Willem Hans Steup; Ad F T M Verhagen; Thomas J van Brakel; Wilhelmina H Schreurs; Michel W J M Wouters
Journal:  Eur J Cardiothorac Surg       Date:  2021-01-04       Impact factor: 4.191

5.  Variation in incidence, prevention and treatment of persistent air leak after lung cancer surgery.

Authors:  Fieke Hoeijmakers; Koen J Hartemink; Ad F Verhagen; Willem H Steup; Elske Marra; W F Boudewijn Röell; David J Heineman; Wilhelmina H Schreurs; Rob A E M Tollenaar; Michel W J M Wouters
Journal:  Eur J Cardiothorac Surg       Date:  2021-12-27       Impact factor: 4.191

6.  Variation Between Multidisciplinary Tumor Boards in Clinical Staging and Treatment Recommendations for Patients With Locally Advanced Non-small Cell Lung Cancer.

Authors:  Fieke Hoeijmakers; David J Heineman; Johannes M Daniels; Naomi Beck; Rob A E M Tollenaar; Michel W J M Wouters; Perla J Marang-van de Mheen; Wilhelmina H Schreurs
Journal:  Chest       Date:  2020-07-30       Impact factor: 9.410

Review 7.  Optimizing lung cancer MDT data for maximum clinical impact-a scoping literature review.

Authors:  Emily Stone; Nicole Rankin; David Currow; Kwun M Fong; Jane L Phillips; Tim Shaw
Journal:  Transl Lung Cancer Res       Date:  2020-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.